Trial reportJAMA network open2026
Adjunctive Psychosocial Interventions and Opioid Abstinence Among Patients Receiving Buprenorphine: A Randomized Clinical Trial.
Trial report in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04257214 (Identifying Optimal Psychosocial Interventions for Patients Receiving Office-Based Buprenorphine), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Identifying Optimal Psychosocial Interventions for Patients Receiving Office-Based Buprenorphine
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Adjunctive psychosocial treatments are recommended for many using medications for opioid use disorder (MOUD), but it is unclear which approaches can best enhance treatment outcomes. Objectives: To evaluate the comparative effectiveness of 2 psychosocial treatments, peer recovery support (PRS) and cognitive-behavioral therapy (CBT), on opioid abstinence when used as adjunctive therapies to office-based buprenorphine treatment in adults with opioid use disorder (OUD). Design, Setting, and Participants: This randomized clinical trial included US adults diagnosed with OUD referred for care at 5 federally qualified health centers with office-based addiction treatment programs by their clinicians from 2020 to 2024. Participants were followed up for 1 year postenrollment. Analyses were conducted September through November 2025. Interventions: Participants were randomized to 1 of 4 conditions: MOUD treatment as usual, MOUD plus 12 weeks of CBT, MOUD plus 12 weeks of PRS, or MOUD plus 12 weeks of CBT and PRS. The CBT intervention consisted of 12 individual, manualized sessions over 12 weeks focused on goal setting, functional analysis, cognitive restructuring, skill building, and relapse prevention. The PRS intervention required at least once-weekly contact for 12 weeks and focused on shared lived experience, goal setting, and navigation assistance to meet immediate needs. In the CBT plus PRS condition, participants were assigned to 12 weeks of concurrent CBT and PRS. Main Outcome and Measure: The primary outcome was urinalysis-confirmed opioid abstinence at 3, 6, 9, and 12 months. Results: A total of 340 participants were included (mean [SD] age, 42.3 [10.9] years; 100 female [29.4%]). Neither CBT (odds ratio [OR], 1.16; 95% CI, 0.63-2.13), PRS (OR, 0.87; 95% CI, 0.48-1.59), nor their interaction (OR, 0.99; 95% CI, 0.30-3.27) was associated with urinalysis-confirmed opioid use. Conclusions and Relevance: In this randomized clinical trial, CBT and PRS had no effect on rates of opioid abstinence in the year following the initiation of MOUD. Trial Registration: ClinicalTrials.gov Identifier: NCT04257214.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.